Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib by Chuah, Charles & Melo, Junia V
© 2009 Chuah and Melo, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
OncoTargets and Therapy 2009:2 83–94
OncoTargets and Therapy
83
r e v i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Targeted treatment of imatinib-resistant chronic 
myeloid leukemia: Focus on dasatinib
Charles Chuah1 
Junia v Melo2
1Singapore General Hospital  
and Duke-NUS Graduate Medical 
School, Singapore; 2institute of 
Medical and veterinary Science, 
South Australia, Australia
Correspondence: Charles Chuah 
Department of Haematology, Singapore 
General Hospital, Cancer and Stem Cell 
Biology Program, Duke-NUS Graduate 
Medical School, Singapore 169608 
Tel +65 6321 4595 
Fax +65 6220 6210 
email charles.chuah.t.h@sgh.com.sg
Abstract: The efficacy of imatinib in chronic myeloid leukemia has been remarkable, but 
the development of resistance and the persistence of minimal residual disease have dampened 
the initial enthusiasm for this much heralded ‘magic bullet’. Much progress has been made in 
elucidating the mechanisms which underlie imatinib resistance. The most common cause of 
such drug resistance is the selection of leukemic clones with point mutations in the Abl kinase 
domain leading to amino acid substitutions which prevent the appropriate binding of the drug. 
Other mechanisms include genomic amplification of BCR-ABL and modulation of drug efflux or 
influx transporters. Dasatinib is a multi-target kinase inhibitor which has increased potency and 
is able to inhibit most Bcr-Abl mutant cell lines. Clinical trials of dasatinib in imatinib-resistant 
and -intolerant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoid 
leukemia have shown that it is effective and well tolerated. In this review, we will discuss the 
pre-clinical development of dasatinib, the clinical trial data demonstrating its efficacy and toler-
ability and highlight certain aspects of its toxicity profile and mechanisms of resistance.
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Introduction
Imatinib has, without doubt, been a major achievement for the treatment of chronic 
myeloid leukemia (CML), but resistance to this drug has become and will continue 
to be a therapeutic challenge. In early chronic phase (CP-CML) patients treated with 
imatinib at diagnosis, 18% failed to achieve a complete cytogenetic response (CCyR) 
after a median follow-up of five years while 6% progressed to the advance phase and 
8% had a cytogenetic or hematologic relapse.1 Among CP-CML patients who had 
failed prior interferon treatment, 43% did not achieve a CCyR after a median duration 
of imatinib treatment of 65 months and 39% progressed to the advance phase.2 Not 
surprisingly, in advanced phase patients treated with imatinib, resistance or relapse 
occurred in 75% of accelerated phase (AP-CML) and 95% of myeloid blast crisis 
(MBC-CML) patients.3 Single agent therapy with imatinib may not be the best long-
term option in CML, at least for a proportion of patients, and other strategies need to 
be explored. Many novel compounds are currently being investigated pre-clinically 
and clinically, and therapeutic approaches to circumvent the problem of imatinib-
resistance are now possible. Dasatinib (BMS-354825, Sprycel; Bristol-Myers Squibb, 
New York, NY) and other Bcr-Abl tyrosine kinase inhibitors (TKI), such as nilotinib 
(AMN107, Tasigna; Novartis, Basel, Switzerland) and bosutinib (SKI-606; Wyeth, 
Madison, NJ) represent the newer generation of TKIs which have been shown to be 
effective and safe in imatinib-resistant and -intolerant CML patients.OncoTargets and Therapy 2009:2 84
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Pre-clinical development  
of dasatinib
The disruption of the proto-oncogene Src is associated 
with the pathogenesis of human cancers.4 Several synthetic 
small molecule inhibitors of Src-family kinases (SFK) have 
been developed, such as PD180970, AP23464, CGP76030, 
dasatinib, and bosutinib. These compounds also inhibit 
Bcr-Abl, Kit and platelet-derived growth factor receptor β 
(PDGFRβ), and have in vitro antiproliferative activity in 
imatinib-sensitive and -resistant CML cells.5–10
Dasatinib was identified among a series of novel 
2-(aminopyridyl)-and 2-(aminopyrimidinyl)-thiazole-
5-carboxamides as a compound with broad spectrum 
antiproliferative activity against hematological and solid 
tumor cell lines, and favorable pharmacokinetics after 
oral dosing.11 X-ray crystallographic studies of the three-
dimensional structure of Abl kinase complexed with dasatinib 
revealed that the compound binds to the activation loop of 
Abl in an active conformation.11 In addition, interactions 
between the Abl ATP-binding site and dasatinib were less 
critical for binding, suggesting that the compound would 
be active against the mutant kinase forms.11 Initial studies 
revealed that dasatinib is a potent multi-target kinase inhibitor 
of Bcr-Abl, SFK (Src, Lck, and Yes), PDGFRβ and Kit at 
nanomolar to sub-nanomolar concentrations (Table 1).11 
Recently, dasatinib was also shown to bind to other tyrosine 
and serine/threonine kinases, such as the TEC family kinases, 
BTK and TEC, the mitogen-activated protein kinases, the 
receptor tyrosine kinase, discoidin domain receptor 1 and 
the ephrin receptors.12
Biochemical assays using purified GST-Abl kinase and 
cellular proliferation and Bcr-Abl tyrosine phosphorylation 
assays revealed that dasatinib was approximately 325 times 
more potent than imatinib.13 Dasatinib was also able to inhibit 
the cellular proliferation, peptide substrate and Bcr-Abl 
tyrosine phosphorylation of all Bcr-Abl mutants at nanomolar 
concentrations with the exception of the T315I mutant.13 In 
addition, in vivo studies in murine models demonstrated the 
activity of dasatinib in inhibiting the leukemic cell growth 
and prolonging the survival of mice harboring wild type Bcr-
Abl and the M351T, but not the T315I mutant.9
Clinical efficacy of dasatinib
Based on the promising pre-clinical data, clinical trials were 
embarked upon to test the efficacy and safety of dasatinib in 
patients who were resistant to or intolerant of imatinib.
Phase i study
CA180002 was a dose-escalation study for patients with 
imatinib-resistant or -intolerant CML or Philadelphia-positive 
acute lymphoblastic leukemia (Ph+ ALL).14 A total of 
84 patients were enrolled into the study. Dasatinib was 
administered at total daily doses ranging from 15 to 240 mg, 
once or twice daily. Dasatinib was generally well tolerated. 
Grade 3 or 4 hematologic suppression was common especially 
in the advanced phases, resulting in treatment interruption 
in 60% and dose reduction in 25% of patients. Nonhemato-
logic toxicities included pleural effusion, diarrhea, nausea, 
vomiting, gastrointestinal hemorrhage, peripheral or 
periorbital edema, pericardial effusion, pulmonary edema, 
rash, flushing headache, fatigue, and tumor lysis syndrome. 
Most of these toxicities were grade 1 or 2 and the maximum 
tolerated dose (MTD) was not determined. Cross-intolerance 
with imatinib was not evident.14
Complete hematologic responses (CHR) were achieved 
in 92% of CP-CML, 45% of AP-CML, 35% of MBC-CML 
and 70% of lymphoid blast crisis (LBC-CML) or Ph+ ALL 
patients. Major cytogenetic remission (MCyR) were also 
observed in 45% of CP-CML, 27% of AP-CML, 35% of 
MBC-CML, and 80% of LBC-CML or Ph+ ALL patients. 
Most of these responses occurred in patients receiving doses 
of 50 to 70 mg twice a day. Responses were seen in patients 
harboring the Bcr-Abl kinase mutations other than the T315I 
mutant.14
Phase ii studies
As the MTD of dasatinib was not defined in the phase I study, 
the phase II dose was based on its efficacy, and all patients, 
regardless of phase of disease, received 70 mg twice daily. 
The START (Src/Abl Tyrosine kinase inhibition Activity: 
Research Trials of dasatinib) clinical trials comprised 
Table 1 Kinase profile of dasatinib
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four single-arm and one randomized phase II studies: 
START-C for CP-CML, START-A for AP-CML, START-B 
for MBC-CML, and START-L for LBC-CML or Ph+ ALL. 
START-R was a randomized trial of dasatinib and high-dose 
imatinib for patients with CP-CML after failure on imatinib 
400 to 600 mg daily.
A total of 387 imatinib-resistant or -intolerant CP-CML 
patients were recruited into the START-C study.15 With a 
median follow-up of 15.2 months, the CHR rates were 91% 
and MCyR rates were 59%. A CCyR was attained in 49% 
of patients. Loss of MCyR occurred in 3% of patients. The 
progression-free survival (PFS) at 15.2 months was 90% and 
the overall survival (OS) was 96%. The causes of death in the 
14 patients were CML disease (n = 6), cardiovascular disease 
(n = 2), infection (n = 2), central nervous system bleeding 
(n = 1), and others (n = 3). The toxicity profile was similar 
to that observed in the phase I study. Approximately 48% 
developed a grade 3 or 4 neutropenia or thrombocytopenia, 
but these were reversible and could be managed with treat-
ment interruption or dose reductions. The most common 
grade 3 or 4 nonhematologic toxicities were pleural effusion 
(6.2%), dyspnea (5.2%), diarrhea (2.8%) and fatigue (2.1%). 
Only 14% of patients had to discontinue treatment due to 
drug-related adverse events. These results confirmed that 
dasatinib was associated with high and durable response rates 
in imatinib-resistant or -intolerant CP-CML patients and had 
a favorable toxicity profile.15
Dasatinib was also clinically effective in the more 
advanced phases. The analysis of 107 AP-CML patents 
enrolled into the START-A trial showed that, at eight 
months’ follow-up, 39% achieved a CHR and 33% 
a MCyR.16 The PFS at 10 months was 76%. A total of 
14 deaths were reported, of which five were due to disease 
progression. Myelosuppression was more frequent in the 
AP-CML patients than in CP-CML. Grade 3 or 4 neutropenia 
and thrombocytopenia occurred in 76% and 82% of patients, 
respectively. However, no patients had to discontinue 
treatment due to infection. Nonhematologic adverse events 
were similar to those of CP-CML.16 Responses were also 
observed in patients with blast crisis but these were generally 
not durable. A total of 109 MBC-CML and 48 LBC-CML 
were enrolled into the study.17 The best CHR rates after a 
minimum follow-up of 12 months were approximately 28% 
in both groups and the best CCyR rates were 26% and 46% 
in the MBC-CML and LBC-CML cohorts, respectively. 
Dasatinib was discontinued in 78% of MBC-CML and 
94% of LBC-CML patients, and this was due to disease 
progression in approximately half of the patients. The median 
PFS was 6.7 months for the MBC-CML and 3.0 months 
for the LBC-CML patients. There was a high frequency of 
grade 3 or 4 cytopenias. Compared to the other phases, severe 
pleural effusion was more frequent in the MBC-CML group, 
occurring in 15% of patients. Febrile neutropenia was the 
most common (15%) grade 3 or 4 nonhematologic adverse 
event in the LBC-CML cohort but it did not lead to the 
discontinuation of dasatinib.17
The START phase II studies revealed that dasatinib 
was effective and safe in imatinib-resistant and -intolerant 
CML, and the results were comparable with the other 
second-generation TKIs (Tables 2–4).15–24
Phase iii dose optimization studies
Pre-clinical investigations in mice bearing a CML xenograft 
showed that maximal inhibition of Bcr-Abl and CrkL 
phosphorylation occurred at approximately three hours after 
a single oral administration of dasatinib.25 This observation, 
together with the phase I study results, led to the selection 
of the dasatinib 70 mg twice daily regimen in the phase II 
studies. However, in the phase I study, similar MCyR rates 
were also achieved in the once daily regimen.14 Longer-
term follow-up also suggested that the frequency of pleural 
effusion was less with the once daily regimen.26 Further-
more, due to dose reductions, the median total daily dose in 
the phase II CP-CML study was 100 mg.15 These findings 
led to the initiation of a phase III study to investigate the 
efficacy and safety of dasatinib administered as a once or 
Table 2 Hematologic and cytogenetic responses in dasatinib phase ii trials
Stage of disease Median duration  
of treatment (months)
CHR (%) MCyR (%) CCyR (%)
CP-CML (n = 387)15 13.8 91 59 49
AP-CML (n = 107)16 8.3 39 33 24
MBC-CML (n = 109)17 3.5 27 33 26
LBC-CML (n = 48)17 2.9 29 52 46
Abbreviations: CHr, complete hematological response; CCyr, complete cytogenetic response; MCyr, major cytogenetic response; CP-CML, chronic phase; AP-CML, 
accelerated phase; MBC-CML, myeloid blast crisis; LBC-CML, lymphoid blast crisis.OncoTargets and Therapy 2009:2 86
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twice daily regimen with a total daily dose of 100 mg or 
140 mg in CP-CML patients who were resistant or intolerant 
to imatinib.
Six hundred and seventy CP-CML patients were 
randomized between four dasatinib treatment arms: 100 mg 
once daily, 50 mg twice daily, 140 mg once daily, or 70 mg 
twice daily.27 With a minimum follow-up of 24 months and 
median treatment duration of 22 months, the CHR rates (87% 
to 92%) and CCyR rates (61% to 63%) were comparable in 
all four groups. Among the patients who achieved a CCyR, 
the median time to CCyR with dasatinib 100 mg once daily 
was 13.0 weeks, compared with 12.9 to 13.8 weeks for the 
other treatment arms. The major molecular response (MMR) 
rate was 38% in the four cohorts. The PFS and OS in the 
100 mg once daily group at 24 months was 80% and 91%, 
respectively. Again, these were comparable to the other 
arms. Significantly, the incidence of pleural effusion of any 
grade in the 100 mg once daily treated patients was less than 
in the other patients (14% versus 23%–25%, p = 0.049). 
Grade 3 or 4 thrombocytopenia was also less frequent in the 
100 mg once daily arm (23% versus 36%–41%, p = 0.003). 
There was a trend towards a lower incidence of grade 3 
or 4 neutropenia in the 100 mg once daily cohort but this 
was not statistically significant (35% versus 44%–47%, 
p = 0.127). Treatment with dasatinib 100 mg once daily 
was also associated with the lowest incidence of treatment 
interruption (62% versus 72%–79%), dose reduction (39% 
versus 46%–62%) and discontinuation due to drug toxicity 
(12% versus 16%–21%).27 These findings confirm that the 
current approved dose of dasatinib 100 mg once daily in 
CP-CML offers the most favorable long-term benefit-risk 
assessment. In addition, these observations are further sup-
ported by a recent study which shows that transient in vitro 
inhibition of Bcr-Abl, through high-dose dasatinib pulse 
therapy, is sufficient to induce irreversible cytotoxicity in 
CML cells.28
The once or twice daily schedule with a total daily dose 
of 140 mg was also investigated in advanced phase patients. 
A total of 317 AP-CML patients was assigned randomly 
to either 140 mg once daily or 70 mg twice daily.29 After 
a minimum follow-up of 24 months, the CHR rates (47% 
versus 52%) and MCyR rates (39% versus 43%) rates were 
similar in the once daily and twice daily arms. The median 
PFS was comparable in the two groups. Patients in the once-
daily arm had significantly fewer pleural effusions of any 
grade compared to those in the twice daily arm (20% versus 
39%, p  0.001). The rates of the other nonhematologic and 
hematologic toxicities were similar between both arms.29 
There was no appreciable difference in efficacy or treatment-
related toxicities in the blast crisis-CML (BC-CML) patients 
who were treated with 140 mg once daily or 70 mg twice 
daily.30 However, there was a suggestion that the once daily 
dose may improve tolerability as evidenced by a lower inci-
dence of dose reduction (4%–6% versus 10%–11%).30
Table 3 Hematologic and cytogenetic responses in nilotinib phase ii trials
Stage of disease Median duration  
of treatment (months)
CHR (%) MCyR (%) CCyR (%)
CP-CML (n = 321)20 19 94 59 44
AP-CML (n = 138)21 8.9 31 32 20
BC-CML (n = 136)22 Nr 11 40 29
Abbreviation: AP-CML, accelerated phase; BC-CML, blast crisis; CP-CML, chronic phase; CHr, complete hematological response; CCyr, complete cytogenetic response; 
MCyr, major cytogenetic response; Nr, not reported.
Table 4 Hematologic and cytogenetic responses in bosutinib phase ii trials
Stage of disease Median duration  
of treatment (months)
CHR (%) MCyR (%) CCyR (%)
CP-CML23 7.3 81 47 34
(102 evaluable) (146 evaluable) (146 evaluable)
AP-CML24 5.5 54 47 27
(24 evaluable) (30 evaluable) (30 evaluable)
BC-CML24 2.5 36 53 35
(14 evaluable) (17 evaluable) (17 evaluable)
Abbreviations: AP-CML, accelerated phase; BC-CML, blast crisis; CCyr, complete cytogenetic response; CP-CML, chronic phase; CHr, complete hematological response; 
MCyr, major cytogenetic response.OncoTargets and Therapy 2009:2 87
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Predictors of response to dasatinib
The knowledge that the Bcr-Abl kinase mutations have 
varying degrees of in vitro sensitivity to dasatinib may allow 
its use in a rational manner. For example, the highly resistant 
T315I mutant would be expected to confer refractoriness to 
dasatinib in patients harboring this mutant. It is also conceiv-
able that patients with mutant clones which have intermediate 
in vitro resistance may not have an optimal response to dasat-
inib. In an analysis of 1,043 CP-CML patients enrolled into 
the phase II and III dasatinib trials, 402 patients had one or 
more baseline Bcr-Abl kinase mutations.31 The T315I mutant 
was detected in 21 patients and not surprisingly, the majority 
did not achieve any response with dasatinib. Excluding the 
T315I mutant, 44 patients had a mutation with a known 
dasatinib cellular IC50 of more than 3 nM (Q252H, E255K/V, 
V299L and F317L). Although responses to dasatinib were 
observed in patients who had any of these five mutations, the 
frequency of responses was less compared to that of patients 
who had mutations with a dasatinib cellular IC50 of less than 
3 nM or with unknown IC50 (Table 5).31
Apart from using existing Bcr-Abl kinase mutations to 
predict response to dasatinib and other second generation 
TKI, it may be possible to predict the probability of achieving 
CCyR using baseline clinical features. A multivariate analy-
sis of 80 imatinib-resistant or -intolerant patients, who were 
treated with dasatinib (n = 67) or nilotinib (n = 13) revealed 
that a low Sokal risk score at diagnosis, the best cytogenetic 
response on imatinib, the use of growth factor support during 
imatinib treatment and the time from detection of imatinib 
failure to commencement of a second generation TKI were 
predictive factors for achieving CCyR.32
Early responses may also be predictive of subsequent 
responses. In a study of 113 patients (87 CP-CML, 
26 AP-CML) who were treated with either dasatinib (n = 70) or 
nilotinib (n = 43), patients who achieved a minor cytogenetic 
response at three or six months, compared to those who did not, 
had a significantly higher probability of achieving a MCyR at 
12 months.33 The molecular response after three months of a 
second generation TKI was also highly predictive of attaining 
a MMR.34 An analysis of 155 CP-CML patients treated with 
dasatinib (n = 82) or nilotinib (n = 73) showed that attaining 
a BCR-ABL transcript level of less than or equal to 1% by the 
International Scale35 at three months resulted in an 86% proba-
bility of achieving a MMR at 24 months. This was significantly 
higher than the probability for those who had a level between 
1% and 10% (55% probability, p = 0.0003) and those with 
levels more than 10% (4% probability, p  0.0001).34 In the 
group with BCR-ABL transcript levels of more than 10% 
by the international scale, those with a level of 50% or more 
had a significantly lower probability of attaining a MCyR at 
24 months, compared to those with levels between 10% and 
50% (11% versus 56%, p = 0.003).34
Therefore, pre-existing Bcr-Abl kinase mutations, certain 
pre-treatment disease features and early cytogenetic and 
molecular responses are useful in predicting the subsequent 
clinical responses in patients on dasatinib therapy.
Significance of dasatinib-induced 
response in CP-CML
In the first-line treatment of CML with imatinib, the achieve-
ment of a MCyR at 12 months and a MMR at 18 months is 
associated with a significantly lower probability of disease 
progression at five years.1 An analysis of 448 imatinib-resistant 
or -intolerant CP-CML patients showed that after 12 months 
of treatment with dasatinib, 57% achieved a MCyR and 45% 
a CCyR.36 Achievement of a MCyR at 12 months was associ-
ated with a higher 24-month PFS of 94%, compared to 79% 
in those who did not (p  0.0001). Likewise, patients who 
achieved a CCyR at 12 months had a higher 24-month PFS 
than those who did not (95% versus 82%, p = 0.0003).36 In a 
separate evaluation of 1,150 CP-CML patients, 35% achieved 
a MMR within a median time of 5.7 months.37 A landmark 
analysis showed that achieving a MMR at 12 months con-
ferred a 24-month PFS of 96% which was significantly higher 
than not attaining that milestone (82%, p  0.0001).37 This 
preliminary data suggest that the attainment of a MCyR, 
CCyR, or MMR at 12 months in dasatinib-treated CP-CML 
patients may lead to a higher PFS.
Dasatinib in the treatment of Ph+ central 
nervous system leukemia
The penetration of imatinib into the cerebrospinal fluid (CSF) 
is poor, leading to insufficient concentrations for kinase 








CHr (%) 82 94 96
MCyr (%) 34 58 73
CCyr (%) 25 47 54
MMr (%) 18 34 43
Notes: aexcluding T315i; bexcluding patients with a concurrent mutation with dasatinib 
iC50  3 nM; cexcluding patients with a concurrent mutation with known dasatinib iC50.
Abbreviations: CHr, complete hematological response; CCyr, complete cytogenetic 
response; MCyr, major cytogenetic response; MMr, major molecular response.OncoTargets and Therapy 2009:2 88
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inhibition.38 Not surprisingly, central nervous system (CNS) 
leukemic relapses are common in imatinib-treated patients 
with LBC-CML, MBC-CML, or Ph+ ALL in spite of com-
plete responses in the peripheral blood and bone marrow.39–42 
A case report of a dasatinib-induced clinical response in Ph+ 
CNS leukemia led to the further investigation of its utility for 
these cases.43 Using a mouse model, where a human CML 
tumor cell line was implanted intracranially, treatment with 
dasatinib significantly increased the median survival time 
compared to the control and the imatinib-treated groups.44 
The antitumor activity, as assessed by bioluminescence 
imaging, was also decreased in the dasatinib-treated group. 
However, when dasatinib was stopped, the intracranial tumors 
recurred and all the mice died. Pharmacokinetic analysis also 
showed that although dasatinib brain concentrations were 
12 to 31 times lower than that in the plasma, the levels were 
adequate to inhibit 50% of cellular proliferation of the CML 
cell line in vitro.44
A study of 11 patients with Ph+ CNS leukemia treated 
with dasatinib revealed that all the patients had a clinical 
response.44 Complete responses were achieved in seven 
patients, of which four were treated with dasatinib alone. 
These responses were durable, lasting between three to 
12 months. Interestingly, dasatinib-resistant Bcr-Abl kinase 
mutants (T315I and V299L) were detected in the CSF 
leukemic blasts of two patients who developed a CNS relapse 
on dasatinib, suggesting that the selection of a resistant 
clone, rather than poor CSF penetration, was the cause of 
relapse.44
Dasatinib in children and adolescents
The role of dasatinib in children and adolescents was 
investigated in a phase I/II dose-finding study which enrolled 
25 patients with CP-CML, advanced phase CML or Ph+ 
acute leukemia, as well as 22 patients with Ph-negative acute 
leukemia.45 The median age was 10 years and all patients 
were heavily pre-treated. Dasatinib was well tolerated up at to 
120 mg/m2 once daily, and the MTD was not reached. CML 
or Ph+ acute leukemia patients were given a dose of 60 or 
80 mg/m2 once daily. Common treatment-related adverse 
events included nausea, vomiting, diarrhea, headache and rash. 
Among the 12 CP-CML patients, 83% achieved a CHR and 
67% a MCyR after a median duration of treatment of 58 days. 
A CHR rate of 23% and CCyR rate of 62% was obtained in 
the 13 advanced phase or Ph+ acute leukemia patients. The 
preliminary findings indicate that dasatinib in effective and 
tolerable in children and adolescents with Ph+ leukemia.45
Dasatinib-related toxicities
Dasatinib is generally well tolerated and its toxicity profile is 
similar, but not identical, to that of the other TKIs (Tables 6 
and 7). However the incidence of cytopenias, pleural effusion 
and immune-mediated adverse events in patients treated 
with dasatinb are higher than those on imatinib or nilotinib 
therapy. This could be due, in part, to dasatinib’s higher 
potency and wider spectrum of kinase inhibition. The fact 
that there is some differential toxicity between the three 
drugs may be actually important and useful for a decision on 
which inhibitor to use or to change to in case of resistance 
to one of them.
Myelosuppression
Regardless of the phase of disease, grade 3 or 4 neutropenia 
and thrombocytopenia occurs more commonly in patients 
treated with dasatinib than those on imatinib, nilotinib or 
bosutinib (Table 6).1,15–24 This is probably a reflection of its 
more potent inhibition of Bcr-Abl and Kit. Myelosuppression 
is generally manageable with dose interruption and reduction. 
The incidence of grade 3 or 4 cytopenia was also reduced in 
CP-CML patients who were treated with the 100 mg once 
Table 6 incidence of grade 3 or 4 cytopenias in phase ii studies
CP-CML (%) AP-CML (%) MBC-CML (%)
imatinib 400 or 600 mg Neutropenia 17 58 64
once daily1,18,19 Thrombocytopenia 9 43 62
Nilotinib 400 mg Neutropenia 31 42 67
twice daily20–22 Thrombocytopenia 31 41 62
Bosutinib 500 mg Neutropenia 12 28 68
once daily23,24 Thrombocytopenia 21 62 76
Dasatinib 70 mg Neutropenia 49 76 80
twice daily15–17 Thrombocytopenia 48 82 82
Abbreviations: AP-CML, accelerated phase; CP-CML, chronic phase; MBC-CML, myeloid blast crisis.OncoTargets and Therapy 2009:2 89
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daily schedule.27 Neutropenia can also be overcome with 
the use of growth factors, thus enabling longer periods of 
uninterrupted dasatinib treatment.46
Pleural effusion
Dasatinib-related pleural effusion is a frequent adverse event 
occurring in 7%–35% of patients, with the lowest frequency 
in CP-CML patients receiving the 100 mg once daily dose 
and the highest in MBC-CML patients receiving the 70 mg 
twice daily dose.15–17,26 The median time from the start of 
dasatinib to the development of pleural effusion was 84 days 
in MBC-CML patients and 315 days in CP-CML patients 
taking dasatinib 100 mg once daily.17,47 Pleural fluid analysis 
revealed that the majority of cases were exudative in nature 
with a predominance of lymphocytes.48,49 The management 
of pleural effusion includes dose interruption and reduction, 
diuretics, corticosteroids and, in severe cases, thoracocen-
tesis.48,49 Two separate multivariate analyses identified that 
certain clinical features were associated with an increased 
risk of developing pleural effusion.48,50 In one study, prior 
cardiac history, hypertension and a twice-daily dasatinib 
schedule were independent predictors for the development of 
pleural effusion.48 In the second study, the associated factors 
were hypercholesterolemia, a history of skin rash on imatinib 
and a previous history of autoimmune disease.50 The latter 
association and the observations that dasatinib-related pleural 
effusion has a lymphocyte predominance and is responsive to 
corticosteroids suggest that the pathogenesis of pleural effu-
sion may be immune-mediated.50 The inhibition of PDGFRβ 
by dasatinib has also been implicated as a cause of pleural 
effusion, and it has been shown that PDGFRβ-deficient 
mouse embryos develop defective blood vessels and edema 
due to a loss of microvascular pericytes.48,51
Dasatinib-induced immune-mediated 
complications
Dasatinib is a potent inhibitor of the SFK member, Lck, 
which is involved in T-cell receptor (TCR) signaling and 
activation.11,52 It has been shown to suppress TCR-mediated 
signaling, cellular proliferation, cytokine production, in vivo 
T-cell responses and in vitro natural killer cell cytotoxicity.52–54 
These findings suggest that patients taking dasatinib may 
be prone to opportunistic infections due to potential T-cell 
inhibition, and that dasatinib may, in fact, have a thera-
peutic role for T-cell mediated immune disorders such as 
graft-versus-host disease or rheumatoid arthritis. However, 
dasatinib-induced Lck inhibition has also been implicated 
in the pathogenesis of autoimmune disorders in two recent 
case reports.49,55 In the first case, the patient presented with 
respiratory symptoms, diffuse ground glass opacities on 
thoracic high-resolution computer tomography and appear-
ance of antinuclear and anti-DNA antibodies after 29 days 
of treatment with dasatinib.49 The second case developed 
fever, arthralgia, pleural effusion, pericardial effusion and 
autoantibodies after 6 months of dasatinib therapy, suggest-
ing a possibility of dasatinib-induced lupus.55 In both cases, 
the autoantibodies were not present before dasatinib. After 
cessation of dasatinib, the symptoms were resolved and the 
autoantibody levels were decreased in the former case and 
were undetectable in the latter.49,55
Another possible mechanism underlying the immune-
mediated toxicities is the clonal expansion of natural killer/
T-cell lineage large granular lymphocytes (LGL). LGL 
lymphocytosis has been observed in patients on dasatinib and 
this correlated with the achievement of complete molecular 
responses.56,57 However, patients with LGL lymphocytosis 
had a high incidence of dasatinib-related adverse events with 
Table 7 incidence of selected nonhematologic toxicities (all grades) in chronic-phase chronic myeloid leukemia patients
Imatinib 400 mg 
once daily (%)90
Nilotinib 400 mg 
twice daily (%)20
Dasatinib 70 mg 
twice daily (%)91
Peripheral edema 56 7 18
Pleural effusion Nr 2 19
elevated ALT/AST 43 68/55 52/60
elevated serum lipase Nr 46 Nr
rash 34 31 22
Nausea 44 25 19
Fatigue 35 20 28
Headache 31 18 34
Muscle cramps 38 Nr Nr
Abbreviation: Nr, not reported.OncoTargets and Therapy 2009:2 90
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more than 50% developing pleural effusion, pneumonitis, 
CMV reactivation, colitis and prolonged fever.57
Mechanisms of resistance 
to dasatinib
Three major mechanisms have been identified for imatinib 
resistance. The two most common affect the BCR-ABL gene 
itself, namely mutations in its tyrosine kinase domain and 
overexpression of the Bcr-Abl protein due to amplification of 
the BCR-ABL gene.58–62 The third mechanism is represented 
by phenomena which lead to Bcr-Abl-independent resistance. 
These include upregulation of the ABCB1 or ABCG2 
drug efflux pumps,58,63,64 downregulation of human organic 
cation transporter 1 (hOCT1) drug influx transporters,65,66 
overexpression of Lyn, a Src-family kinase,67 and other 
Bcr-Abl-independent mechanisms. Dasatinib, due to its 
increased potency and efficacy against most of the imatinib-
resistant Bcr-Abl kinase mutations, has been able to over-
come most forms of imatinib resistance mediated by the 
former two mechanisms. However, resistance to dasatinib 
has also become an emerging therapeutic problem.
Dasatinib-resistant Bcr-Abl kinase 
mutations
Pre-clinical in vitro and in vivo studies have shown that 
the T315I mutant is resistant to dasatinib.9,13 The dasatinib 
cellular IC50 for this mutant is more than 250 times higher 
than that for wild type Bcr-Abl, and kinase activity is not 
inhibited even in the presence of micromolar concentrations 
of the drug.9,13 Dasatinib treatment did not reduce leukemic 
burden nor improve survival of mice harboring the T315I 
mutant.68 Co-crystal studies have demonstrated that the T315 
is a critical contact residue for dasatinib.69 Dasatinib interacts 
with the side chain of T315 by a hydrogen bond and loss 
of this hydrogen bond in the T315I mutant, together with 
an increased steric bulk in this pocket, are the most likely 
causes of dasatinib resistance.69 Not surprisingly, nearly all 
imatinib-resistant patients with the T315I mutant did not 
have any clinical response to dasatinib.15–17,31,70
Using two different in vitro mutagenesis screening tech-
niques, twelve Bcr-Abl mutants at six sites were identified 
which conferred in vitro resistance to dasatinib (Table 8).71,72 
Crystallographic studies have shown that four of these six 
sites (L248, V299, T315, and F317) are dasatinib contact 
residues.69 Dasatinib makes contact with L248 and G321 by 
van der Waals interactions and the 2-chlor-6-methyl phenyl 
ring of dasatinib occupies a hydrophobic pocket composed of 
T315, M290, V299, I313, and A380.69 The aromatic ring in 
the side chain of F317 interacts directly with the pyrimidine 
and thiazole rings of dasatinib.69
Consistent with the in vitro mutagenesis data, the selec-
tion of the V299L, T315I, and F317L mutants has been 
implicated in the emergence of resistance in patients treated 
with dasatinib.70,73–77 Four separate studies have shown that 
the T315I mutant accounted for 8% to 70% of dasatinib-
resistant mutations31,70,73–75 A possible explanation for the 
wide variation is that the studies with a higher incidence of 
T315I mutant had a larger proportion of BC-CML and Ph+ 
ALL patients.
The F317L mutant has intermediate in vitro resistance 
to dasatinib.13 Although CHR were achieved with dasatinib 
in imatinib-resistant patients harboring this mutant, MCyR 
were attained in less than 10%.31 The F317L mutant was 
also detected in 12% to 42% of patients who developed 
resistance to dasatinib.31,70,73–75 The median OS of patients 
with the F317L was 19 months from the time of detection 
and this was similar to that of patients with other mutations.76 
The survival was dependent on the phase of disease and the 
two-year OS was 75% in CP-CML, 50% in AP-CML, and 
20% in BC-CML patients.76
The V299L mutant was detected in 12% to 25% of 
dasatinib-resistant patients.31,73,74 This is a novel mutation 
that had rarely or never been seen in imatinib-resistant 
patients.74,77 The V299L mutant retains in vitro sensitivity 
to imatinib and nilotinib and clinical responses have been 
observed in patients treated with these compounds.73,77
Table 8 Bcr-Abl mutants recovered in the presence of dasatinib 
and cellular iC50
Predicted mutation Bradeen et al71 Burgess et al72
L248r + (12)
L248v + (2)
Q252H + (2) + (Nr)
e255K + (7) + (9.7)
v299L + (13.4) + (13.4)
T315A + (93)
T315i + (250) + (750)
F317C + (Nr)
F317i + (Nr) + (Nr)
F317L + (9) + (13.4)
F317S + (Nr)
F317v + (40) + (40)
Notes: ( ) = Fold dasatinib iC50 wild type Bcr-Abl.OncoTargets and Therapy 2009:2 91
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A possible strategy to suppress the outgrowth of resistant 
clones is the combination of dasatinib or the other Bcr-Abl 
TKIs with an inhibitor of T315I. SGX393 is an azaindole 
which inhibits the growth of cells expressing wild type 
Bcr-Abl and the T315I mutant, as well as other Bcr-Abl 
mutants at varying concentrations.78 SGX393 also reduced 
CrkL phosphorylation in primary hematopoietic cells from 
patients harboring the T315I mutant and inhibited growth of 
T315I-driven tumors in mice.78 In addition, the combination 
of dasatinib and SGX393 completely inhibited the growth of 
mutant clones at most dose combinations except at intermedi-
ate concentrations of dasatinib and SGX393.78
Dasatinib cellular influx and efflux
Multidrug resistance (MDR) due to cross-resistance of 
mammalian cells to a number of anticancer agents following 
exposure to one such drug is a well described mechanism 
of resistance in cancer therapy. This is mediated by an 
increased expression at the cell surface of the ABCB1 gene 
product, P-glycoprotein, an energy dependent efflux pump, 
which reduces intracellular drug concentrations and leads to 
ineffective levels of the drug reaching its target.79 Imatinib is 
a substrate of ABCB1, and the intracellular levels of imatinib 
were shown to be significantly lower in ABCB1-expressing 
cells.65,80–82 However, ABCB1 overexpression has not been 
reported in patients who are resistant to imatinib. Two other 
drug transporters, ABCG2 and hOCT1, have been implicated 
as possible mechanisms for promoting imatinib resistance. 
Imatinib has been reported to be a substrate and/or an inhibi-
tor for the ABCG2 drug efflux pump which is overexpressed 
in many human tumors and also found to be functionally 
expressed in CML stem cells.64,83,84 The drug transporter 
hOCT1 mediates the active transport of imatinib into cells, 
and inhibition of hOCT1 decreases the intracellular concen-
tration of imatinib, which may predict for a less favorable 
molecular response.65,66
The cellular influx of dasatinib, on the other hand, is not 
affected by hOCT1 activity, although its efflux may be medi-
ated by ABCB1 and ABCG2.85,86 The intracellular concentra-
tion of dasatinib was lower in ABCB1-overexpressing cell 
lines and was increased in the presence of PSC833, a potent 
ABCB1 inhibitor.85 The in vitro concentration of dasatinib 
required to inhibit phosphorylation of CrkL by 50% (dasatinib 
IC50) was higher in the ABCB1-overexpressing cell lines 
compared to parental cell lines (100 nM versus 7 nM), and this 
was reduced to 8 nM with the addition of PSC833.85 Similar 
results were also seen in the ABCG2-overexpressing cell 
lines, suggesting that high levels of ABCG2 reduced dasatinib 
intracellular concentration, leading to an increased dasatinib 
IC50, which can be modulated with ABCG2 inhibitors.85
The intracellular concentration of dasatinib in primary 
cells from CP-CML patients was not significantly decreased 
with the addition of hOCT1 inhibitors.85,86 Dasatinib IC50 was 
also not significantly different in hOCT1-overexpressing or 
control cell lines and in cells from patients with high or low 
hOCT-1 activity.85,86 In addition, there was no correlation 
between the intracellular concentration of dasatinib and 
dasatinib IC50 in newly diagnosed CP-CML patients.85
Disease persistence
Small numbers of primitive nondividing stem cells have 
been identified to be refractory to the pro-apoptotic effect of 
imatinib and conventional chemotherapeutic agents.87 The 
insensitivity of these ‘quiescent’ cells also has important 
implications for the management of CML with regards to 
minimal residual disease and relapse following imatinib-
induced response. Although dasatinib significantly inhibited 
CrkL phosphorylation and caused a reduction in the total 
number of CD34+CD38- CML cells compared to imatinib, 
it did not eliminate the most primitive, quiescent fraction.88 
Recently, the farnesyl transferase inhibitor, BMS-214662 
was reported to enhance the cytotoxic effect of imatinib or 
dasatinib in primary CD34+ CML cells and significantly 
reduce the numbers of undivided primitive quiescent CML 
stem cells, either alone or in combination with imatinib or 
dasatinib.89 This effect was selective and normal stem cells 
were relatively spared. The cytotoxic action was via apoptosis 
as evidenced by enhanced caspase-3 activity.89 BMS-214662 
is currently in phase I trials in acute myeloid leukemia and 
the possibility of clinical trials in CML is being explored.89
Conclusion
Dasatinib, through its increased potency and ability to bind 
Bcr-Abl with less stringent conformational requirements, 
is clinically effective in the treatment of imatinib-resistant 
CML, leading to durable hematologic and cytogenetic 
responses and improved PFS and OS. It is generally well 
tolerated but, due to its wider spectrum of kinase inhibition, 
certain toxicities occur more frequently than with other TKIs. 
Dasatinib resistance, due to Bcr-Abl kinase mutation and 
potentially overexpression of drug efflux transporters, will 
represent the next therapeutic challenge in CML. Pre-clinical 
data suggests that combination treatment may prevent the 
selection of resistant mutants and eradicate primitive stem 
cells but this will require clinical validation and will represent 
the next phase of development.OncoTargets and Therapy 2009:2 92
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